Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 7/20 | 0.75 |
| ▸ | JAK1 | P23458 | 10/20 | 0.63 |
| ▸ | AURKA | O14965 | 2/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.50 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.50 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.50 |
| ▸ | JAK3 | P52333 | 2/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
| ▸ | NEK1 | Q96PY6 | 2/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21044783 | 0.87 | JAK2 (0.65) | JAK2JAK1AURKAAURKBINCENP | |
| SCHEMBL19832260 | 0.86 | JAK2 (1.00) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL19832101 | 0.86 | JAK2 (1.00) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL29540487 | 0.85 | AURKB (0.60) | JAK2JAK1AURKAAURKBINCENP | |
| SCHEMBL101177 | 0.85 | AURKB (0.60) | JAK2JAK1AURKAAURKBINCENP | |
| SCHEMBL28107488 | 0.85 | AURKB (0.57) | JAK2JAK1AURKAAURKBINCENP | |
| Trifluoroacetic Acid SCHEMBL4094031 | 0.84 | JAK2 (0.54) | JAK2JAK1AURKAAURKBINCENP | |
| SCHEMBL99992 | 0.81 | AURKA (0.52) | JAK2JAK1AURKAAURKBINCENP | |
| SCHEMBL4094038 | 0.81 | JAK2 (0.51) | JAK2JAK1AURKAAURKBINCENP | |
| Trifluoroacetic Acid SCHEMBL101253 | 0.80 | JAK2 (0.50) | JAK2JAK1AURKAAURKBINCENP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190270740-A1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | TIANJIN LONGBOGENE PHARMACEUTICAL CO., LTD. (CN) | 2019-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270740-A1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885AURKA 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.